Forsta Ap Fonden Novo Cure LTD Transaction History

Forsta Ap Fonden

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$56.6 - $89.9 $147,160 - $233,740	2,600 New	2,600 $181,000
Q3 2021 Nov 10, 2021	SELL	$116.17 - $194.55 $2.52 Million - $4.22 Million	-21,700 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$130.4 - $225.58 $456,400 - $789,530	3,500 Added 19.23%	21,700 $4.81 Million
Q1 2021 May 11, 2021	BUY	$124.11 - $190.17 $248,220 - $380,340	2,000 Added 12.35%	18,200 $2.41 Million
Q4 2020 Feb 09, 2021	BUY	$112.16 - $174.14 $1.82 Million - $2.82 Million	16,200 New	16,200 $2.8 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.37B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Forsta Ap Fonden, based on Form 13F filings with the SEC.

Stay updated on Forsta Ap Fonden with notifications on news.